Talk:Microdosing

Microdosing (also known as psychedelic microdosing) is the practice of using sub-threshold doses of a psychedelic substance in an attempt to produce a therapeutic or nootropic effect. Microdosing has been claimed by some to have a wide range of benefits including enhancing productivity, treating symptoms of psychological disorders such as clinical depression and adult ADD/ADHD, boosting creativity and problem-solving abilities, as well as increase spiritual awareness. There is currently no clinical evidence to support these claims, however a number of small scale studies have shown positive outcomes. In 2020 a study by the Beckley Foundation found that a 20 microgram dose of LSD significantly reduced pain perception when compared to a placebo, with results comparable to those observed after administration of opioids.

While the practice has its origins with LSD, it is in theory possible to microdose with any psychedelic substance. There are a growing body of reports of microdosing psilocybin mushrooms, or psychedelic research chemicals, particularly LSD analogs such as ALD-52, 1P-LSD, AL-LAD and ETH-LAD.

Microdoses range from about one tenth of an active dose. A microdose of LSD is generally considered to be between 5-15 micrograms. This can be measured accurately using volumetric dosing techniques. A microdose of psilocybin mushrooms is harder to determine due to the variations in potency between species and batches; it is generally advised to start with no more than .25g.

Subjective effects

The panels below list the effects generally occur at a microdose dose for psychedelic substances according to reports by PsychonautWiki contributors.

Psychedelics

• Visual

  • Enhancements (sub-perceptual)

• Other

  • Analysis enhancement (sub-perceptual)
  • Conceptual thinking (sub-perceptual)
  • Creativity enhancement (sub-perceptual)
  • Emotionality enhancement (sub-perceptual)
  • Novelty enhancement (sub-perceptual)
  • Spirituality enhancement (sub-perceptual)

Dissociatives

• • Anxiety suppression (sub-perceptual)
  • Cognitive euphoria (sub-perceptual)
  • Depersonalization (sub-perceptual)
  • Derealization (sub-perceptual)

Stimulants

• • Focus enhancement (sub-perceptual)
  • Stimulation (sub-perceptual)
  • Thought acceleration (sub-perceptual)
  • Wakefulness (sub-perceptual)

Cannabis

• • Conceptual thinking (sub-perceptual)
  • Sedation or stimulation (sub-perceptual) (depending on the strain)
  • Thought connectivity (sub-perceptual)
  • Thought deceleration (sub-perceptual)

Benzodiazepines

• • Anxiety suppression (sub-perceptual)

Opioids

• • Pain relief (sub-perceptual)

See also

• Psychedelics
• Volumetric liquid dosing

External links

• Microdosing (Wikipedia)
• Psychedelic microdosing (Wikipedia)

Literature

• Horsley, R.R., Páleníček, T., Kolin, J., & Valeš, K. (2018). Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats. Behavioural Pharmacology. https://doi.org/10.1097/FBP.0000000000000394

References

This article does not cite enough references. You can help by adding some.